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roles in both intestinal homeostasis and human disease.
Although often referred to as the mucosal or intestinal barrier
for its ability to limit harmful molecules or antigens in the
lumen from entering the body, the intestinal epithelium also
allows for paracellular transport of ﬂuid, ions, and nutrients that
are crucial for normal gut function. A key structural component
of the mucosal barrier that contributes to intestinal epithelial
permeability is the intracellular tight junction, and defects in the
tight junction barrier have been implicated in the etiology of
chronic intestinal inﬂammation. In this issue of The American
Journal of Pathology, Al-Sadi et al1 report on the molecular
mechanisms and intracellular pathways involved in increased
intestinal tight junction permeability mediated by the pro-
inﬂammatory cytokine, tumor necrosis factor-a (TNF-a).
The hypothesis that increased intestinal permeability
contributes to the pathogenesis of inﬂammatory bowel dis-
ease (IBD) was ﬁrst described by Shorter et al2 in the early
1970s. Although several studies followed showing an as-
sociation with decreased barrier function in patients with
Crohn’s disease,3e5 it was Hollander et al6 who ﬁrst
demonstrated that both Crohn’s disease patients and a subset
of their healthy relatives have a primary defect in intestinal
permeability. Other groups expanded these ﬁndings and
provided a genetic link (NOD2 3020insC) for the increased
intestinal permeability observed in ﬁrst-degree relatives of
patients with Crohn’s disease.7e9 Collectively, these studies
support the concept that increased intestinal permeability
may predispose one to develop chronic intestinal inﬂam-
mation through increased transport of luminal antigens.
TNF-a has been shown to induce intestinal epithelial cell
permeability through the increased expression and activation
of myosin light-chain kinase (MLCK).10e14 Monoclonal an-
tibodies directed against TNF-a have shown improvement inCopyright ª 2013 American Society for Investigative Pathology.
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http://dx.doi.org/10.1016/j.ajpath.2013.10.001clinical aspects of the disease,15e17 as well as a reduction in
mucosal pro-inﬂammatory cytokine production.18 Further-
more, the work of Suenaert et al19 showed that the intestinal
tight junction barrier in patients with active Crohn’s disease
could be restored with anti-TNF treatment. Although mono-
clonal antibodies to TNF-a, such as inﬂiximab, have shown
promise in the treatment of intestinal inﬂammation, there is
limited knowledge regarding the intracellular mechanisms
involved in the TNF-aemediated increase in intestinal epi-
thelial cell permeability.Bridging the Gap between TNF-a Signaling and
Tight Junction Function in Vitro
In this issue of AJP, Al-Sadi et al1 reveal the counterparts of
a signaling pathway initiated in the inﬂamed intestinal
epithelium due to a rise in TNF-a. The group established the
relevance of their in vitro model, colonic epithelial CaCo2
cells, for the study of TNF-aeinduced tight junction
dysfunction by showing that treatment of CaCo2 mono-
layers with this pro-inﬂammatory cytokine causes increased
transepithelial ﬂux. Moreover, the downstream target of
TNF-a involved in epithelial barrier function, MLCK, was
also increased in TNF-a treated CaCo2 monolayers.
Because TNF-a is known to activate mitogen-activated
protein (MAP) kinases, the group went on to investigate the
Commentaryrole of MAP kinases in epithelial barrier function. They
showed that TNF-a activates the MAP kinases ERK1/2, but
does not affect p38. Pharmacological inhibition or siRNA
silencing of ERK1/2 reversed the effect of TNF-a onMLCK
gene expression and subsequently restored transepithelial
resistance in CaCo2 monolayers, suggesting that ERK1/2
has a key role in the regulation of intestinal barrier function.
In an effort to connect ERK1/2 signaling with the regu-
lation of MLCK gene expression, this study focused on the
transcription factor Elk-1, a known downstream target of
MAP kinases. With the use of in silico analysis, the authors
identiﬁed two Elk-1 binding motifs on the promoter region
of the MLCK gene, with only one of them being adequate
and sufﬁcient to promote MLCK gene expression in CaCo2
cell monolayers. TNF-a induces Elk-1 activation in an
ERK1/2-dependent manner, whereas both ERK1/2 and
Elk-1 are necessary for MLCK gene expression and the
reduction of tight junction function in CaCo2 monolayers,
thus conﬁrming the importance of this signaling pathway in
the regulation of tight junction permeability in vitro. How-
ever, how relevant and important is this molecular pathway
for the regulation of intestinal barrier function in vivo?Conﬁrming the Importance of the TNF-a/ERK1/
2/Elk/MLCK-Dependent Barrier Function
in Vivo: Tools for Future Therapeutic Targets
The ﬁnal parts of this study include experiments conﬁrming
in vitro ﬁndings in an in vivo model. Here, the authors used
a relatively new and sophisticated technique to silence
intracellular molecules in vivo. An initial evaluation of the
mouse model for relevance was performed to show that
intestinal permeability was increased after intraperitoneal
administration of TNF-a. The authors also showed that
ERK1/2 and Elk-1 activity, as well as MLCK gene expres-
sion, were upregulated after TNF-a treatment.The American Journal of Pathology - ajp.amjpathol.orgPerhaps the most important ﬁndings of this study involve
the application of an in vivo silencing approach using
siRNA. This group has knocked down target molecules after
in vivo transfection of siRNA with similar efﬁcacy in pre-
vious studies.20,21
In these experiments, the authors selectively knocked
down the expression of ERK1/2 or Elk-1 in the intestine
with siRNA in vivo, thus inhibiting the effect of TNF-a on
intestinal barrier function.
Today, the pro-inﬂammatory effects of TNF-a are
commonly treated with antieTNF-a antibodies that have
taken the lead in development of immune-modulating drugs
because TNF-a is known to be an important cytokine in gut
diseases such as Crohn disease and ulcerative colitis.17,22e24
As intravenous administration of any drug presents with a
number of limitations, a more localized approach could
potentially optimize treatment options. Al-Sadi et al1 were
able to block downstream targets of TNF-a and reverse pro-
inﬂammatory effects in a localized manner, suggesting an
alternative approach for treatment without the side effects of
a systemically administered drug. In particular, the authors
restored intestinal barrier function by targeting two separate
TNF-a downstream molecules, directly to the mouse in-
testine. As shown in Figure 1, development of drugs that
silence the expression of ERK1/2 or Elk-1 would prevent
MLCK gene expression, thus restoring tight junction and
intestinal barrier function.
An important question that needs to be addressed after this
study is whether in vivo silencing of ERK1/2 and/or Elk-1
ameliorates the colitis phenotype in relevant colitis mouse
models. Both the trinitrobenzene sulfonic acid (TNBS) and
the dextran sodium sulfate (DSS) colitis mouse models, as
well as the immune models of intestinal inﬂammation, are
widely accepted models for the study of inﬂammatory bowel
disease. For example, future studies should address the extent
of colitis in mice treated with siRNA against ERK1/2 or
Elk-1 targeted to the intestine in vivo.Figure 1 A: Schematic representation of the
intracellular pathways involved in increased in-
testinal tight junction permeability mediated by
the pro-inﬂammatory cytokine, TNF-a. B: Targeted
silencing of ERK1/2 or Elk-1 expression prevents
MLCK gene expression, thus restoring tight junc-
tions and intestinal barrier function.
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Bakirtzi et alMore importantly, the ﬁndings in the line of work dis-
cussed in this commentary suggest that similar in vivo
silencing may be applied on other intracellular molecules
exerting pro-inﬂammatory effects in the gut. The develop-
ment of drugs that administer such silencing agents to the
site of injury in the intestine should become a major focus in
the ﬁeld of gastroenterology.References
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